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ABSTRACT  
 
Trans-10, cis-12 conjugated linoleic acid (CLA) is a fatty acid intermediate 
produced during rumen biohydrogenation of dietary linoleic acid, and it is a potent 
inhibitor of milk fat synthesis in the cow.  Inhibition of milk fat synthesis by CLA has 
also been demonstrated in rodent models.  The objective of the present study was to 
determine whether dietary fat level affects the response of the mammary gland to CLA in 
lactating mice.  Wild type C57Bl/6J mice (n = 31) nursing 6-8 pups were fed semi-
purified diets containing either 4% fat (LF) or 24% fat (HF) starting 4-6 d after 
parturition.  High oleic acid sunflower oil was substituted for corn starch to increase the 
fat content of the HF diet.  After a 2 d pretreatment period, lactating dams were orally 
dosed with either water (control) or trans-10, cis-12 CLA (20 mg/d, divided among three 
equal doses) for 5 d.  CLA treatment decreased growth of the nursing litter similarly for 
both diets; no effect of dietary fat or interaction with CLA was observed.  Dam energy 
intake was decreased by CLA, but this effect was partially attenuated by increased dietary 
fat.  Milk fat percent was increased 16-17% by the HF diet and decreased 12-13% by 
CLA.  Both CLA and the HF diet reduced the proportion of short and medium chain fatty 
acids in milk fat.  These fatty acids originate from de novo synthesis in the mammary 
gland.  Conversely, the milk fat concentration of fatty acids >16 carbons in length was 
increased 62-63% by the HF diet, and substantial incorporation of dietary oleic acid into 
milk fat was observed.  In conclusion, CLA caused a reduction in milk fat percent and 
litter growth that was not overcome by increased dietary fat.  
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INTRODUCTION 
 
The inhibition of milk fat synthesis by isomers of conjugated linoleic acid (CLA) 
is a well-studied and physiologically relevant example of nutritional genomics, the 
modulation of gene expression by specific bioactive dietary components.   Originally 
recognized in dairy cows, these unique fatty acid isomers are produced in the rumen 
under conditions of altered biohydrogenation and cause a coordinated downregulation in 
the expression of genes for key lipogenic enzymes (1).  The result is a specific reduction 
in milk fat, commonly known as milk fat depression.  Recent research has examined the 
mechanism by which CLA isomers inhibit milk fat synthesis, and the sterol response 
element binding protein (SREBP) transcription factor system and the nuclear protein 
thyroid hormone responsive spot 14 have been implicated (2).  To investigate the 
mechanism further, our lab has validated a lactating mouse model to allow for nutritional 
genomic investigation (3).  Oral administration of trans-10, cis-12 CLA, the first CLA 
isomer shown to inhibit milk fat synthesis, caused a dose-dependent decrease in milk fat 
in the mouse and a shift in fatty acid profile comparable to that observed in the dairy cow 
(3).  Although the reduction in milk fat involves fatty acids of all chain lengths, the 
greatest decrease is seen for short and medium chain fatty acids that are synthesized in 
the mammary gland by the process of de novo lipogenesis. 
The interaction of CLA and diet is an important factor in further understanding 
the regulation of milk fat synthesis by CLA.  Whereas the range of possible dietary 
interventions is limited in the cow by the necessity of maintaining an appropriate 
environment for rumen microorganisms, a mouse model provides more freedom to 
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manipulate diet composition.  Of particular interest is the potential role of dietary fat in 
affecting the response of the mammary gland to CLA.  Altering the amount and source of 
fat in the diet is known to affect the quantity and composition of milk fat in rodents (4-7).  
This raises the question of whether the changes in milk fat percent and fatty acid profile 
in response to CLA are modulated by the fat content of the diet, and that is the focus of 
this thesis.   
 
REVIEW OF LITERATURE 
 
CLA studies in dairy cows: the milk fat depression story 
CLA has been studied most extensively in the dairy cow, where it is linked to the 
phenomenon of milk fat depression (MFD).  First described in 1885, MFD is 
characterized by a reduction in milk fat and a change in fatty acid composition (8).  This 
effect is specific to fat; milk protein and yield are not affected.  MFD is observed with 
certain diets, particularly diets that are low in forage or supplemented with 
polyunsaturated fatty acids.  Although many theories have been proposed to explain the 
incidence of diet-induced MFD, most have proven inadequate (8).  However, the 
“biohydrogenation theory” proposed by Bauman and Griinari (9) has gained widespread 
support in recent years.  It proposes that low fiber diets cause changes in the rumen 
environment that alter the pathways of biohydrogenation, leading to the production of 
unique fatty acid isomers that inhibit milk fat synthesis.  This idea grew out of studies 
from the 1960’s that identified an increase in the milk fat content of trans 18:1 fatty acid 
isomers in milk fat-depressed cows (8).  These trans fatty acids are indicative of 
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incomplete biohydrogenation by rumen bacteria, and it was suggested that they might 
directly inhibit milk fat synthesis (9).  Later experiments linked MFD with a specific 
increase in trans-10 18:1 rather than trans 18:1 isomers in general (10).  A putative 
pathway for the formation of trans-10 18:1 was then proposed (Figure 1).  Dietary 
linoleic acid is normally isomerized to cis-9, trans-11 CLA, which is then reduced to 
trans-11 18:1 and finally stearic acid (9).  Under conditions of MFD, a minor pathway 
comes into play in which linoleic acid is instead converted to trans-10, cis-12 CLA and 
trans-10 18:1 before reaching stearic acid.  This alternate pathway has been supported by 
the isolation of rumen bacteria capable of producing trans-10, cis-12 CLA (11)  or trans-
10 18:1 (11, 12).  Ruminal infusions of trans-10, cis-12 CLA result in elevated plasma 
trans-10 18:1, providing additional evidence for the precursor/product relationship of 
these two fatty acids (13). 
 
  
 
 
 
 
 
 
 
 
 
FIGURE 1.  Pathways of rumen biohydrogenation of linoleic acid.  Adapted from 
Bauman and Griinari (9). 
 
 
The first specific inhibitors of milk fat synthesis identified were isomers of CLA.  
This was discovered in a study investigating the possibility of enhancing the CLA content 
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of milk to exploit the known positive health effects of CLA (14).  A mixture of CLA 
isomers was abomasally infused, with the unexpected consequence of a 55% reduction in 
milk fat yield.  One of the isomers was trans-10, cis-12 CLA, which was subsequently 
demonstrated to cause MFD when infused as a 90% pure preparation (15).  Two more 
biohydrogenation intermediates have since been shown to inhibit milk fat synthesis, cis-
10, trans-12 CLA (16) and trans-9, cis-11 CLA (17).  Others are suspected, but the 
limited availability of pure isomers has hampered the investigation of bioactive fatty 
acids. 
 A number of studies involving the abomasal infusion of trans-10, cis-12 CLA 
have yielded similar shifts in the fatty acid composition of milk as those seen during diet-
induced MFD.  In both cases, the yield of fatty acids of all chain lengths is reduced; 
however, the decrease in de novo synthesized fatty acids is most prominent (8).  As a 
result, these short- and medium-chain fatty acids constitute a smaller proportion of the 
total fatty acids.  High doses of trans-10, cis-12 CLA (≥7 g/d) inhibit the activity of 
stearoyl CoA desaturase (SCD) (18), an enzyme in the mammary gland that introduces a 
cis-9 double bond in fatty acids.  This also affects the fatty acid composition of milk by 
increasing the ratios of several SCD substrate/product pairs, including C14/C14:1, C16/C16:1, 
and C18/C18:1 (18).  These ratios are often used as a proxy for SCD activity.  Changes in 
the desaturase index are not consistently observed with lower doses of trans-10, cis-12 
CLA or during diet-induced MFD (19).  Thus the inhibition of milk fat synthesis does not 
necessarily require a reduction in desaturase activity (18). 
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Mechanism of CLA-induced milk fat depression 
 Both low fiber diets and trans-10, cis-12 CLA cause downregulation in the 
expression of a number of genes encoding key lipogenic enzymes in the mammary gland.  
These are involved in the uptake and transport of fatty acids from the circulation 
(lipoprotein lipase [LPL]and fatty acid binding proteins [FABP]), de novo synthesis of 
fatty acids (acetyl CoA carboxylase [ACC] and fatty acid synthase [FASN]), and 
triglyceride synthesis (glycerol phosphate acyltransferase [GPAT] and acylglycerol 
phosphate acyltransferase [AGPAT]) (20, 21).  Expression of SCD is also reduced, as 
noted above.  The wide range of enzymes affected is consistent with the observed 
reductions in the yield of fatty acids derived from both de novo synthesis and uptake of 
preformed fatty acids from the blood.   
The coordinated down-regulation of genes involved in milk fat synthesis 
suggested the role of a global regulator of gene expression.  The sterol regulatory element 
binding protein (SREBP) family of transcription factors was identified as a candidate 
system (20).  This was supported by the fact that all of the CLA-responsive genes named 
above contain sterol regulatory elements (SRE) and are thus potentially responsive to 
SREBP (20).  Proteolytic cleavage of SREBP is required to produce the nuclear fragment 
(nSREBP) that binds to the SRE of target genes and stimulates transcription (22).  
Treatment of bovine mammary epithelial cells with trans-10, cis-12 CLA reduced the 
level of nSREBP without the altering the amount of the precursor protein, suggesting that 
CLA inhibits the proteolytic cleavage of SREBP1 (22).  In vivo, the abundance of 
SREBP1 mRNA was decreased during diet-induced MFD and treatment with trans-10, 
cis-12 CLA (2).  The expression of several proteins involved in the proteolytic activation 
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of SREBP1 was also reduced in one or both conditions.  These observations support the 
role of the SREBP transcription factor system in the regulation of milk fat synthesis 
during diet-induced MFD and trans-10, cis-12 CLA treatment. 
Another gene, thyroid hormone responsive spot 14 (S14), has also been 
implicated in the regulation of gene expression by trans-10, cis-12 CLA (2).  S14 is 
associated with de novo fatty acid synthesis, and its mRNA abundance is well correlated 
with the lipogenic rates of the tissues in which it is expressed (23).  Little is known about 
its biochemical function, but S14 is a nuclear protein (24) that interacts with transcription 
factors (25).  Its promoter contains a SRE (26), making S14 expression responsive to 
nSREBP (27).  Indeed, mammary gland mRNA abundance of S14 is reduced during diet-
induced MFD and treatment with t10, c12 CLA (2).  The role of S14 in lipogenesis has 
been supported by experiments using an antisense oligonucleotide to inactivate S14 
mRNA.  This decreased the expression of lipogenic enzymes in rat hepatocytes and 
diminished triglyceride synthesis (28).  Additional evidence came from a S14 knockout 
mouse model in which de novo fatty acid synthesis in the mammary gland was reduced 
and the milk fat percent was lowered (23).  Interestingly, S14 is used as a marker for 
aggressive breast cancers (29), which are noted for their high rates of lipid synthesis (30).  
The suppression of S14 expression and lipogenesis by trans-10, cis-12 CLA provides a 
link to the observed anticarcinogenic properties of CLA (31).  
 
CLA studies in rodents 
 Supplementation of CLA as 0.5-2.0% of the diet has been demonstrated to reduce 
body fat accretion in mice (32, 33), and most rodent studies of CLA examine this anti-
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obesity effect.  In contrast, the effects of CLA on lactation in rodents occur at much lower 
doses; as little as 6.5 mg trans-10, cis-12 CLA per day (equivalent to 0.07% of the diet) 
has been shown to inhibit milk fat synthesis in mice (3).  However, relatively few studies 
have investigated the effects of CLA in lactating rodents.   
 The earliest rodent studies of the effects of CLA on milk fat synthesis employed 
supplements containing a mixture of isomers of CLA (34-36).  There are over 20 
geometric and positional isomers of CLA (37), and little is known about the biological 
effects of most of them.  Of the eight CLA isomers that have been abomasally infused as 
pure preparations, three have been demonstrated to inhibit milk fat yield in the dairy cow 
(1).  As mentioned previously, these are trans-10, cis-12 CLA, trans-9, cis-11 CLA, and 
cis-10, trans-12 CLA.  The CLA supplements that have been fed to lactating rodents 
contain a wide range of CLA isomers, but trans-10, cis-12 CLA, cis-11, trans-13 CLA, 
cis-9, trans-11 CLA, and trans-8, cis-10 CLA have predominated in the two studies that 
reported the composition of the CLA supplement used.  These four isomers accounted for 
65% of the mix used by Ringseis et al. (35) and 91% of the total CLA fed by Hayashi et 
al. (36).  In these studies, the supplement provided trans-10, cis-12 CLA as 0.47% (36) or 
0.56% of the diet (35).   
In both cases, CLA supplementation in lactating rats decreased milk fat and litter 
growth and shifted the fatty acid composition of the milk (35, 36).  These changes were 
more extensive for Ringseis et al. (35), who reported greater reductions in milk fat (46% 
vs. 33%) and litter weight or growth (35% vs. 21%) than Hayashi et al. (36).  Whereas 
changes in the fatty acid profile reflected decreased de novo lipogenesis in both studies, 
the decrease in short and medium chain fatty acids reported by Ringseis et al. (35) was 
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greater (28% vs. 12%); additionally, the incorporation of trans-10, cis-12 CLA into milk 
fat was also considerably greater (2.5% vs. 0.6%) despite similar doses of this isomer.  
These differences may be attributable to variation in the composition of the CLA 
supplement used and the interval of treatment.  Hayashi et al. (36) fed their CLA 
supplement for the first 16 d of lactation, whereas the rats studied by Ringseis et al. (35) 
were treated for several weeks prior to breeding, throughout pregnancy, and up to 17 d 
following parturition.  This longer treatment period may have resulted in greater 
incorporation of CLA isomers into adipose and liver triglycerides during growth.  
Mobilization of these lipid stores during lactation and uptake by the mammary gland 
could have contributed to the greater concentration of trans-10, cis-12 CLA in the milk.  
However, compared to other species, mobilization of body fat to support lactation 
typically plays a less substantial role in the adaptation of rodents to the metabolic 
demands of lactation, as rodents increase their feed intake greatly to supply substrates for 
milk production (38). 
In contrast to these two studies, Chin et al. (34) did not observe an inhibitory 
effect of CLA supplementation on pup growth.  During pregnancy and the first 10 d of 
lactation, rats were fed a supplement providing 0.25% or 0.5% total CLA as a percentage 
of the diet.  The authors did not provide the isomer composition of the CLA supplement.  
A 9% increase in average pup weight was observed for the 0.5% CLA group, but there 
was no significant difference at the 0.25% dose.  Mean pup weight was numerically 
increased for rats fed 0.5% CLA only during lactation, but this difference was not 
significant.  Milk fat percentages were not reported in this paper, but the authors 
indicated by personal communication that no differences were found.  Without 
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information on the CLA isomers fed by Chin et al. (34), it is difficult to explain the 
conflicting observations of this study and those by others (35, 36).  It is quite possible 
that the supplements contained different proportions of trans-10, cis-12 CLA and other 
isomers that inhibit milk fat synthesis.  Also, the highest CLA dose used by Chin et al. 
(34) was roughly a third of total concentration of CLA isomers fed in the other two 
studies.  Nevertheless, had the supplement contained as little as 10% trans-10, cis-12 
CLA (0.05% of the diet), a decrease in pup growth would be expected based on the 
response to treatment with pure trans-10, cis-12 CLA at 0.07% of the diet (3).   
All three studies employing CLA mixtures in lactating rats attest to the 
relationship of milk fat and pup growth.  When a reduction in milk fat was reported, a 
decrease in pup growth was also seen.  This association between milk composition, 
particularly fat content, and pup growth is consistently observed in conditions other than 
CLA treatment.  For instance, Del Prado et al. (39) altered milk fat concentration by 
feeding diets with varying fat content and noted corresponding effects on pup growth.  
Additionally, parameters of pup growth were positively correlated with milk fat across 
four strains of mice (40).  Although other components of milk are responsive to dietary 
manipulations, the fat content of milk is of particular importance to the nutrition and 
growth of pups because fat is the primary energy source in milk (38). 
Studies of pure isomers of CLA in rodents are even more limited.  Loor et al. (41) 
compared the effects of trans-10, cis-12 CLA (0.91% of diet) and cis-9, trans-11 CLA 
(0.96% of diet) in lactating mice between days 4 and 15 of lactation.  Consistent with 
abomasal infusion studies in dairy cows (15, 42, 43), cis-9, trans-11 CLA had no effect 
on milk fat or litter weight whereas trans-10, cis-12 CLA decreased these parameters by 
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29% and 25%, respectively.  A shift in milk fatty acid profile characteristic of decreased 
de novo lipogenesis was also observed.  Additionally, the authors noted that two of the 
six mice treated with trans-10, cis-12 CLA drastically reduced their feed intake and 
stopped lactating.  This observation may be related to the dose of trans-10, cis-12 CLA 
used, which was nearly twice the amount fed in the studies employing mixtures of CLA 
isomers.   
A study in our lab involving administration of pure trans-10, cis-12 CLA at 
varying doses to lactating mice also provided evidence of impairment of lactation due to 
high doses of CLA (3).  Mice were orally dosed with 6.5, 20, or 60 mg/d of trans-10, cis-
12 CLA for a period of 5 d starting at day 6-8 of lactation.  Based on the recorded feed 
intake for each treatment group, these doses were equivalent to 0.07%, 0.23%, and 0.77% 
of the diet, respectively.  The 60 mg dose produced a 49% reduction in pup growth, but 
no change in milk fat percent was observed.  However, mammary lipogenesis, as 
measured by the rate of incorporation of 14C-labeled glucose into lipid by tissue explants, 
was decreased by 40%.  The considerable reductions in pup growth and lipogenesis 
without any decrease in milk fat percent were interpreted as evidence for a general 
inhibition of lactation.  A reduction in lactose synthesis would depress milk yield, thus 
affecting the concentration of other milk components including fat.   
 Whereas high doses of trans-10, cis-12 CLA appear to impair lactation, low to 
moderate doses (0.07-0.23% of diet) cause a specific and dose-dependent reduction in 
milk fat and consequently pup growth (3).  The 6.5 mg dose corresponding to 0.07% of 
the diet produced numerical decreases in lipogenesis and milk fat.  Pup growth and the 
percent of fat in milk clots collected from the stomachs of the pups were significantly 
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decreased by 20% and 13%, respectively.  The 20 mg dose of trans-10, cis-12 CLA 
caused significant reductions in milk fat (20%), clot fat (16%), lipogenesis (30%), and 
pup growth (19%).  All three doses altered the composition of milk fat; the proportion of 
short and medium chain fatty acids derived from de novo lipogenesis was progressively 
decreased in a dose-dependent manner. 
Studies of CLA in rodents have also reported decreases in the mRNA abundance 
and activity of several key lipogenic enzymes in the mammary gland.  Changes include 
reduced mRNA expression and activity of FASN (3, 35, 36, 44) and ACC (44), two 
enzymes involved in de novo lipogenesis.  Also, Hayashi et al. (36) reported decreased 
activity of glucose 6-phoshphate dehydrogenase (G6PDH) and 6-phosphogluconate 
dehydrogenase (6PGDH) in mammary tissue.  These enzymes are part of the pentose 
phosphate pathway, which generates reducing equivalents for fatty acid synthesis.  
However, NADPH is also derived from the malate pathway, and activity of the key 
enzyme NADP-malate dehydrogenase (NADP-MDH) was unchanged.  The authors 
suggested that NADPH production appeared to not be the rate limiting factor in de novo 
lipogenesis (36).  Enzymes involved in other processes related to milk fat production are 
also downregulated.  Decreased abundance of LPL mRNA (35) and decreased mRNA 
abundance and activity of SCD (44) have been observed in response to treatment with 
CLA.   
 
Effects of dietary fat on rodent lactation 
 A number of studies have examined the effects of varying the content and 
composition of dietary fat on milk fat, mammary lipogenesis, and pup growth.  Results 
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from rodent studies have been somewhat mixed.  Several studies have reported that high 
fat diets increase milk fat percentage (4, 39, 45, 46), while others have found no change 
(5, 47-50) or even a decrease in milk fat (51).  There is also disagreement over whether 
high fat diets increase pup growth (5, 39, 45) or have no effect (6, 47, 48, 51, 52).  Of the 
studies that measured mammary lipogenesis, most observed a decrease (4-6), whereas 
one found no change (46). 
 These differences may be attributable to variations in methodology, percent of 
dietary fat in the control and high fat diets, treatment period, fat source, species, and/or 
other factors.  For instance, lipogenesis assays were either conducted in vivo using 
tritiated water (4-6) or in vitro using mammary explants (46).  The latter method 
measures the lipogenic capacity of mammary tissue in the presence of abundant 
substrates for fatty acid synthesis, whereas in vivo measurements reflect rates of fatty acid 
synthesis that are occurring as a consequence of the availability of precursors for de novo 
lipogenesis.  High fat diets ranged from 15 to 55% fat and were compared to control diets 
containing 0 to 12% fat.  Some investigators substituted additional fat for carbohydrates 
in the diet; others merely added fat to the control diet.  The latter approach changes the 
proportion of protein and other essential nutrients on a dry matter basis, which can affect 
the nutritional status of the dam and pups independently of the fat content of the diet.  
Studies also differed in the period over which the experimental diets were fed; the 
feeding duration for the experimental diet varied from as little as 3 d to several months.  
In one case, dams were raised on the high and low fat diets from birth (50).  Long term 
feeding of a high fat diet has been demonstrated to induce obesity and impair mammary 
development and lactogenesis in mice (53).   
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 Different sources of dietary fat can also contribute to the variation among studies.  
Common fat choices were corn oil (4, 39, 46, 51) and lard (48, 49, 52).  Two studies 
compared high fat diets of different compositions and observed that the response varied 
based on the source of dietary fat.   In the experiments of Grigor and Warren (5), rats 
were fed diets containing 20% oil that represented peanut oil, coconut oil, or linseed oil; 
these high fat diets all reduced the rate of mammary lipogenesis in vivo, although the 
reduction was greatest for the peanut oil diet.  The peanut oil diet was also the only one to 
produce a significant increase in pup growth.  Souza and Williamson (6) found differing 
responses to diets consisting of 20% tristearin, sunflower oil, triolein, or medium chain 
fatty acids.  Compared to a control diet containing 4% fat, the reduction in mammary 
lipogenesis, assessed in vivo using tritiated water, ranged from 57% for the medium chain 
fatty acid diet to 92% for the sunflower oil diet.  Medium chain fatty acids decreased pup 
weight by 35%, but no changes were observed for the other diets.  Energy intake by the 
dam also varied by diet; it was significantly increased in the tristearin group and 
decreased in the medium chain fatty acid group.   
 Differences in the physiological properties of fatty acids affect their metabolic 
disposition and their impact on milk fat synthesis.  Unlike long chain fatty acids, medium 
chain fatty acids are not re-esterified and packaged into chylomicra following absorption 
in the gut (54).  As a result, these fatty acids are extensively oxidized for energy in the 
liver, decreasing their availability for incorporation into milk fat.   This is illustrated by 
the observation of Souza and Williamson (6) that 65% of 14C-labeled octanoate (8:0) 
supplied in a meal was oxidized to 14CO2, and only 0.2% of the absorbed dose was 
recovered in mammary tissue.  In comparison, 38% of 14C-triolein (18:1) added to the 
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diet was oxidized, and 3.2% ended up in mammary lipids. Dietary polyunsaturated fatty 
acids such as those found in sunflower oil and peanut oil are known to inhibit lipogenesis 
by regulating gene transcription (55).  These bioactive fatty acids therefore modulate the 
activity of lipogenic enzymes not just as substrates but also by controlling gene 
expression.  This may account for the more pronounced inhibition of mammary 
lipogenesis by high fat diets containing polyunsaturated fatty acids from peanut oil or 
sunflower oil. 
 The reduction in mammary lipogenesis typically observed due to high fat diets 
shifts the fatty acid profile of milk fat (e.g. 4).  The proportion of short and medium chain 
fatty acids decreases, reflecting reduced de novo synthesis, and long chain fatty acids 
comprise a greater percent of the total (4).  These fatty acids are derived from the uptake 
of preformed fatty acids from plasma lipoproteins or circulating nonesterified fatty acids.  
Since rodents adapt to lactation by dramatically increasing feed intake, many of these 
long chain fatty acids originate from the diet.  Consequently, the fatty acid profile of milk 
fat reflects the fatty acid composition of the diet.  This is particularly evident when 
dietary fat sources are compared (5, 7, 50).   
 A crossover study by Teter et al. (50) demonstrated that isomers of trans-18:1 
appear in milk fat within 6 h of switching from a diet consisting of predominantly cis 
fatty acids to one high in trans isomers.  The concentration of trans fat in milk reached a 
stable plateau within 2 d and dropped dramatically within 1 d when trans fatty acids were 
removed from the diet.  Teter et al. (50) also compared cis and trans fat diets at different 
levels of total dietary fat.  The authors did not observe an effect of fat level on milk fat, 
but the presence of a high concentration of trans fatty acids in the diet decreased milk fat 
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percent for mice fed both low fat and high fat diets.  No interaction was found between 
the amount of fat in the diet and the proportion of cis or trans fatty acids.  The trans fat 
diets contained partially hydrogenated fat from margarine, which has been demonstrated 
to contain a range of isomers of CLA (56).  Some of these CLA isomers may have 
contributed to the observed effects on milk fat, but the hydrogenation process generates a 
number of other unusual fatty acids that are potentially bioactive.  To the best of our 
knowledge, the effect of dietary fat level on the ability of pure trans-10, cis-12 CLA to 
inhibit milk fat synthesis in lactating rodents has not been examined.   
 
OBJECTIVE 
 
 The overall goal of this thesis was to investigate the interrelationship between 
dietary fat and bioactive fatty acids in the regulation of milk fat synthesis.  The specific 
objective of the present experiment was to examine the effect of dietary fat level on the 
ability of the trans-10, cis-12 isomer of CLA to inhibit milk fat synthesis in a lactating 
mouse model. 
 
MATERIALS AND METHODS 
 
Animals and treatments 
 C57Bl/6J mice were obtained from The Jackson Laboratory (Bar Harbor, ME), 
and maintained in accordance with the National Institutes of Health guidelines for animal 
care.  Experimental procedures were approved by the Cornell University Institutional 
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Animal Care and Use Committee.  Females were bred in groups to wild type males and 
subsequently housed individually in shoe box cages with continuous access to food and 
water.  Mice were fed a commercial pelleted diet containing 5% fat (Harlan Teklad, 
Madison, WI) during pregnancy and early lactation.  Litters born to dams in their first (n 
= 17), second (n = 13), or third (n = 1) lactation were adjusted to 6-8 pups by cross-
fostering within 2 d of parturition.  Dams were randomly assigned to one of four 
treatments in a 2x2 factorial design.  Mice were fed diets either low or high in fat (4% 
and 24%, respectively) and received oral doses of either water (control) or trans-10, cis-
12 CLA (20 mg/d).  Thus the treatments were low fat diet control (LFCON), low fat diet 
with CLA (LFCLA), high fat diet control (HFCON), and high fat diet with CLA 
(HFCLA).  Experimental diets were provided ad libitum starting between days 4-6 of 
lactation.  CLA treatment began 2 d later and lasted for a period of 5 d.   
 Pelleted semi-purified diets were prepared by Research Diets (New Brunswick, 
NJ).  The high fat (HF) diet was formulated by substituting Trisun high oleic sunflower 
oil for cornstarch in the low fat (LF) diet (Table 1).  Diet fatty acid composition (Table 
2) was determined by the method of Sukhija and Palmquist (57).  Briefly, ground feed 
samples were heated in 5% methanolic HCl at 70° C for 2 h as part of a one-step method 
to extract and esterify feed fatty acids.  A triglyceride composed of 17:0 was used as an 
internal standard.  Fatty acid methyl esters were quantified by gas chromatography using 
a fused-silica capillary column (CP-Sil 88; 100 m x 0.25 mm internal diameter; Varian, 
Inc., Walnut Creek, CA) as described by Perfield et al. (17). 
 CLA was administered by pipette into the mouth of the dam in three equal doses 
per day (0900, 1700, and 2400 h).  Control mice received a similar volume of water at 
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each time point.  The CLA stock (Natural ASA, Norway) was in free fatty acid form and 
contained 89.0% trans-10, cis-12 CLA, 2.0% linoleic acid, and <0.9% of any other 
individual fatty acid.  CLA and other fatty acids were purified from the stock solution by 
hexane:isopropanol extraction according to Hara and Radin (58). 
 
TABLE 1 
Diet composition 
  Low fat diet (LF) High fat diet (HF)
  g% a kcal%b g%  kcal% 
Casein, 80 Mesh  18.96 19.72 23.31 19.72
L-Cystine  0.28 0.30 0.35 0.30
Corn starch  47.39 49.30 16.97 14.35
Maltodextrin 10  9.48 9.86 11.65 9.86
Sucrose  9.48 9.86 11.65 9.86
Cellulose, BW200  4.74 0 5.83 0
Soybean oil  2.37 5.55 2.91 5.55
Trisun high oleic sunflower oil  1.90 4.44 20.68 39.39
Mineral mix S10026  0.95 0 1.17 0
Dicalcium phosphate  1.23 0 1.51 0
Calcium carbonate  0.52 0 0.64 0
Potassium citrate, 1 H2O  1.56 0 1.92 0
Vitamin mix V10001  0.95 0.99 1.17 0.99
Choline bitartrate  0.19 0 0.23 0
FD&C yellow dye #5  0.002 0 0.003 0
FD&C red dye #40  0.002 0 0 0
FD&C blue dye #1  0 0 0.003 0
Protein 19.2 20.0 23.7 20.0
Carbohydrate 67.3 70.0 41.4 35.0
Fat 4.2 10.0 23.6 45.0
Total kcal/g 3.85  4.73
  
a  g/100 g of diet (dry weight) 
b  % energy of diet 
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TABLE 2 
Fatty acid composition of experimental diets 
a  c, cis 
 Low fat diet (LF) High fat diet (HF) 
Fatty acida g/100 g total fatty acids
8:0 0.03 0.01
10:0 0.07 0.02
12:0 2.25 1.35
14:0 4.06 0.68
14:1c9 0.01 0.33
16:0 7.12 3.70
16:1c9  0.11 0.08
18:0 3.01 2.52
18:1c9  45.93 78.41
18:2c9,12  30.01 10.49
18:3c9,12,15 2.64 0.64
Others 4.76 1.77
  
 
 
Data and sample collection 
 Dams, litters, and feed were weighed daily between 0900 and 1000 h for temporal 
analysis of litter growth and dam energy intake.  Average litter growth rate and energy 
intake for the last 3 d of treatment were also used for determination of treatment effects.  
Following day 5 of CLA treatment, pups were euthanized by CO2 asphyxiation at 1130 h, 
and milk clots were collected from their stomachs.  Clots were composited by litter, 
freeze-dried, and stored at -80° C.  Later the same day, dams were anesthetized and 
milked at 1430 h.  Oxytocin (7 USP; VEDCO, St. Joseph, MO) was administered IP 5 
min prior to IP injection of 0.2 mL of a solution of either tribromoethanol (32 mg/mL; 
Avertin, Sigma-Aldrich, St. Louis, MO) or ketamine/xylazine (10 mg/mL ketamine 
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[Ketaset, Fort Dodge Animal Health, Fort Dodge, IA], 1 mg/mL xylazine [Anased, Ben 
Venue Laboratories, Bedford, OH]).  Dams were milked by manually massaging the 
mammary glands to express droplets of milk, which were collected into a 2 mL 
siliconized microcentrifuge tube (ISC BioExpress, Kaysville, UT) with the aid of a 
vacuum source.  The milking apparatus and procedure are described more completely by 
Harvatine et al. (3).  Milk samples were immediately diluted 1:1 with isotonic saline and 
sonicated to improve pipetting ease.  Aliquots of diluted milk were stored at -80° C until 
analysis.  After milking, dams were euthanized by cervical dislocation while under 
anesthesia, and tissues were collected.  The liver was weighed, and a #3 mammary gland 
was fixed in 10% neutral buffered formaldehyde.  Mammary tissue was embedded in 
paraffin, sectioned, and stained with hematoxylin and eosin by the Cornell Veterinary 
School Histology Lab (Ithaca, NY).   
 
Sample analysis 
 Fat content and fatty acid profiles were determined for milk obtained from dams 
and milk clots collected from pup stomachs.   Lipids were extracted in duplicate from 
approximately 60 mg diluted milk or 20 mg freeze-dried clot using hexane:isopropanol 
(58).  Two internal standards, a triglyceride containing 17:0 and 19:0 fatty acid methyl 
ester, were added prior to extraction for determination of fat concentration.  Milk fatty 
acids were transmethylated and quantified by gas chromatography as described 
previously (17).  A dual methylation procedure was used for clot lipids; fatty acids were 
first methylated overnight at 40° C in 1% methanolic sulfuric acid (59) and subsequently 
transmethylated and quantified as described for milk fat.   
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Statistical analysis 
 Endpoint variables were analyzed by the fit model procedure of JMP (Version 
7.0; SAS Institute, Cary, NC).  The model included the effects of diet (LF vs. HF), CLA 
(control vs. CLA), and the interaction of diet and CLA.  Initial litter weight was added as 
a covariate in the models for litter weight gain and dam energy intake, and initial dam 
body weight was used as a covariate in the liver weight model.  Effects of diet and CLA 
were considered significant at p < 0.05, and interactions were considered significant at p 
< 0.10.  Preplanned contrasts tested the differences between LFCON and LFCLA and 
between HFCON and HFCLA.  Data points with Studentized residuals >2.5 were 
excluded as outliers.   
 Temporal responses of litter weight gain and dam energy intake were analyzed by 
the mixed procedure of SAS (Version 9.1; SAS Institute, Cary, NC) using a repeated 
statement.  The model included the fixed effects of treatment (LFCON, LFCLA, 
HFCON, or HFCLA), the interaction of treatment and time, and in the model of energy 
intake, the covariate initial dam body weight.  Repeated measures over time were 
calculated using the autoregressive covariance structure [AR(1)], and denominator 
degrees of freedom were estimated using the Kenward Rogers method.  Data points with 
Studentized residuals >3 were excluded from analysis.  Preplanned contrasts tested the 
differences between LFCON and LFCLA and between HFCON and HFCLA at each time 
point. 
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RESULTS 
 
Production parameters 
 CLA treatment decreased litter growth by 19-21% (p < 0.001; Table 3).  No 
effect of diet or interaction between diet and CLA was observed (p = 0.18 and 0.69, 
respectively).  Temporal analysis indicated that the reduction in litter growth due to CLA 
was evident for all 5 d of treatment for mice on the LF diet and for days 2-4 for mice on 
the HF diet (p < 0.05; Figure 2A).  Energy intake was increased for dams on the HF diet 
(p < 0.01) and decreased by treatment with CLA (p < 0.0001; Table 3).  An interaction 
between diet and CLA was observed (p < 0.01); the reduction in voluntary intake due to 
CLA was greater for mice on the LF diet (27%) than those on the HF diet (14%).  Energy 
intake by dams on the HF diet was nearly double that of dams on the LF diet for the first 
day that the experimental diets were offered (Figure 2B).  Energy intakes on the 
following day were similar.  CLA decreased energy intake for the entire 5 d treatment 
period for mice on the LF diet but only for days 2 and 4 for mice on the HF diet (p < 
0.05).  Administration of CLA to dams resulted in weight loss (p = 0.04), but dam live 
weight was only numerically decreased for dams on the LF diet (Table 3).  Dam liver 
weight was increased 2-4% for mice on the HF diet (p < 0.01), but CLA had no effect on 
liver weights (Table 3).   
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TABLE 3 
Effect of dietary fat level and trans-10, cis-12 conjugated linoleic acid (CLA) on 
production and milk fat concentration of lactating C57Bl/6J mice 
 Treatmenta SEM P 
 LFCON LFCLA HFCON HFCLA  Diet CLA Diet*CLA 
Litter growth, g/db 2.84 2.30d 3.11 2.45e 0.08 0.18 <0.001 0.69 
Dam energy intake, kcal/db 36.23 26.45d 36.24 31.26 e 0.36 <0.01 <0.0001 <0.01 
Dam weight change, g/dc -0.01 -0.15 0.07 0.07 0.04 0.58 0.04 0.63 
Liver weight, g 1.88 1.92 1.65 1.72 0.03 <0.01 0.35 0.78 
Milk fat, % 19.92 17.44d 23.25 20.29e 0.38 <0.001 <0.01 0.75 
Pup stomach clot fat, % 58.89 49.07d 59.16 55.38 0.75 0.04 <0.001 0.05 
         
a  Treatments were LFCON (4% fat diet, no CLA), LFCLA (4% fat diet, 20 mg/d CLA), 
HFCON (24% fat diet, no CLA), and HFCLA (24% fat diet, 20 mg/d CLA).  Diets 
were fed to dams for 7 d in midlactation; CLA was orally administered for the last 5 d 
of the treatment period.  Values are LS means; n = 7 for LFCON, and n = 8 for all other 
treatments. 
b  Average for last 3 d of treatment period 
c  Average for last 3 d of treatment period 
d  Significantly different from LFCON (p < 0.05) 
e  Significantly different from HFCON (p < 0.05) 
 
 
Milk and clot fat content and composition 
 Milk fat percent was increased 16-17% for the HF diet (p < 0.001) and decreased 
12-13% by CLA (p < 0.01; Table 3).  No interaction was observed between diet and 
CLA.  The percent of fat in milk clots collected from the stomachs of pups nursing dams 
on the LF diet was decreased 17% by CLA; a lesser reduction (6%) was observed for 
pups of dams on the HF diet (interaction: p = 0.05; Table 3).  Considering both control 
and CLA-treated animals, the overall effect of the HF diet was an increase in clot fat 
percent (p = 0.04).  However, this was primarily due to the less dramatic reduction in clot 
fat percent due to CLA when the HF diet was fed; clot fat percent was similar for the 
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LFCON and HFCON treatments.  Milk clots from pups nursing HFCLA dams contained 
a greater percent of fat than those of pups nursing LFCLA dams, but both had lower clot 
fat percents than the controls.  
 
 
FIGURE 2.   Temporal response of litter growth (A) and dam energy intake (B) in 
lactating C57Bl/6J mice fed low fat (4% fat; LF) or high fat (24% fat; HF) diets and 
orally dosed with water (control; CON) or trans-10, cis-12 conjugated linoleic acid (20 
mg/d; CLA) in the specified combinations for the intervals indicated.  Litter growth rates 
were significantly different (p < 0.05) between LFCON and LFCLA on days 1-5 and 
between HFCON and HFCLA on days 2-4.  Energy intakes were significantly different 
(p < 0.05) between LFCON and LFCLA on days 1-5 and between HFCON and HFCLA 
on days 2 and 4.  Values are LS means; n = 7 for LFCON, and n = 8 for all other 
treatments. 
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Increased dietary fat and treatment with CLA both altered the fatty acid profile of 
milk fat (Table 4).   The HF diet decreased milk fat concentrations of 8:0, 10:0, 12:0, 
14:0, 16:0, and 16:1c9 and increased the concentrations of 18:1c9, 18:2c9,12, 
18:3c9,12,15, and 20:0.  In particular, the milk fat content of 18:1c9 was increased from 
29.29 to 56.46 g/100 g of fatty acids for control mice fed the HF diet.  CLA decreased the 
concentrations of 12:0, 14:0, 16:0, and 18:3c9,12,15 and increased the concentrations of 
18:0, 18:1c9, 18:2c9,12, and 20:0.  Trans-10, cis-12 CLA was not detected in the milk of 
control mice but composed 0.61 and 0.36 g/100 g of fatty acids in the milk of LFCLA 
and HFCLA mice, respectively.  The concentrations of individual fatty acids in clot fat 
differed somewhat from their concentrations in milk fat, but similar patterns of changes 
were observed in response to the HF diet and CLA treatment (Table 5).  In both milk fat 
and milk clot fat, interactions between diet and CLA were observed for several fatty acids 
(Tables 4 and 5).  Those that were consistently seen were for 10:0, 16:1c9, and 20:0.  
CLA increased the concentrations of 10:0 and 16:1c9 when the LF diet was fed but not 
when the HF diet was fed.  The concentration of 20:0 was significantly increased by CLA 
for both diets, but the magnitude of the increase was greater for the LF diet.  
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TABLE 4 
Effect of dietary fat level and trans-10, cis-12 conjugated linoleic acid (CLA) on milk 
fatty acid profile of lactating C57Bl/6J mice 
 Treatmenta SEM P 
 LFCON LFCLA HFCON HFCLA  Feed CLA Feed*CLA 
Fatty acid, g/100 gb
   8:0 0.18 0.28 0.18 0.13 0.02 0.02 0.43 0.04 
   10:0 4.07 5.80d 3.26 2.20 0.26 <0.001 0.53 0.01 
   12:0 8.99 7.96 5.57 2.90e 0.24 <0.0001 <0.001 0.09 
   14:0 12.91 7.60d 6.59 2.65e 0.22 <0.0001 <0.0001 0.13 
   14:1c9 0.42 0.32 0.21 0.27 0.04 0.09 0.83 0.27 
   16:0 21.29 17.76d 11.03 7.97e 0.17 <0.0001 <0.0001 0.48 
   16:1c9 3.07 3.68d 0.71 0.68 0.03 <0.0001 0.22 0.08 
   18:0 1.66 2.11d 1.69 2.04e 0.05 0.84 <0.001 0.61 
   18:1c9 29.36 32.33d 56.46 65.39e 0.47 <0.0001 <0.0001 <0.01 
   18:2c9,12 8.47 10.11d 7.60 8.84e 0.00 <0.0001 <0.0001 0.91 
   18:3c9,12,15 1.84 1.27d 1.88 1.56e 0.03 0.01 <0.0001 0.03 
   20:0 0.03 0.10d 0.05 0.10e 0.62 <0.0001 <0.0001 <0.0001 
   t10, c12 CLA 0.00 0.61d 0.00 0.36e 0.03 0.02 <0.0001 0.02 
Total by source, g/100 gc
   <16 carbons 26.63 22.17d 15.88 8.20e 0.63 <0.0001 <0.0001 0.21 
   16 carbons 25.28 21.49d 11.74 8.66e 0.20 <0.0001 <0.0001 0.39 
   >16 carbons 41.45 48.25d 67.77 78.39e 0.56 <0.0001 <0.0001 0.10 
         
a  Treatments were LFCON (4% fat diet, no CLA), LFCLA (4% fat diet, 20 mg/d CLA), 
HFCON (24% fat diet, no CLA), and HFCLA (24% fat diet, 20 mg/d CLA).  Diets 
were fed to dams for 7 d in midlactation; CLA was orally administered for the last 5 d 
of the treatment period.  Values are LS means; n = 7 for LFCON, and n = 8 for all other 
treatments. 
b  c, cis; t, trans 
c  Total by source: fatty acids <16 carbons are derived from mammary de novo 
lipogenesis; fatty acids >16 carbons are taken up preformed from plasma; fatty acids 16 
carbons in length originate from both sources. 
d  Significantly different from LFCON (p < 0.05) 
e  Significantly different from HFCON (p < 0.05) 
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TABLE 5 
Effect of dietary fat level and trans-10, cis-12 conjugated linoleic acid (CLA) on the fatty 
acid profile of milk clots from the stomachs of C57Bl/6J pups 
 Treatmenta SEM P 
 LFCON LFCLA HFCON HFCLA  Feed CLA Feed*CLA 
Fatty acid, g/100 gb
   8:0 0.03 0.01 0.03 0.03 0.00 0.30 0.45 0.53 
   10:0 3.60 4.72d 2.82 2.30 0.10 <0.0001 0.15 <0.001 
   12:0 11.11 11.16 6.58 3.97e 0.14 <0.0001 <0.001 <0.0001 
   14:0 16.24 11.48d 7.96 3.54e 0.16 <0.0001 <0.0001 0.59 
   14:1c9 0.23 0.11d 0.06 0.04 0.01 <0.0001 <0.0001 <0.001 
   16:0 27.45 18.75d 12.26 7.66e 0.16 <0.0001 <0.0001 <0.0001 
   16:1c9 2.64 2.82 0.61 0.43e 0.03 <0.0001 0.97 0.01 
   18:0 1.85 1.96d 1.62 1.87e 0.02 <0.001 <0.0001 0.06 
   18:1c9 22.17 30.39d 55.78 66.69e 0.42 <0.0001 <0.0001 0.12 
   18:2c9,12 7.88 10.43d 7.50 8.81e 0.08 <0.0001 <0.0001 <0.001 
   18:3c9,12,15 1.16 1.25d 1.71 1.59e 0.01 <0.0001 0.66 <0.001 
   20:0 0.11 0.39d 0.18 0.30e 0.01 <0.001 <0.0001 <0.0001 
   t10, c12 CLA 0.00 0.37d 0.00 0.28e 0.01 0.07 <0.0001 0.107 
Total by source, g/100 gc
   <16 carbons 31.55 27.55d 17.52 10.02e 0.35 <0.0001 <0.0001 0.02 
   16 carbons 30.19 21.59d 12.87 8.09e 0.17 <0.0001 <0.0001 <0.0001 
   >16 carbons 33.27 44.62d 66.85 79.70e 0.45 <0.0001 <0.0001 0.41 
         
a  Treatments were LFCON (4% fat diet, no CLA), LFCLA (4% fat diet, 20 mg/d CLA), 
HFCON (24% fat diet, no CLA), and HFCLA (24% fat diet, 20 mg/d CLA).  Diets 
were fed to dams for 7 d in midlactation; CLA was orally administered for the last 5 d 
of the treatment period.  Values are LS means; n = 7 for LFCON, and n = 8 for all other 
treatments. 
b  c, cis; t, trans 
c  Total by source: fatty acids <16 carbons are derived from mammary de novo 
lipogenesis; fatty acids >16 carbons are taken up preformed from plasma; fatty acids 16 
carbons in length originate from both sources. 
d  Significantly different from LFCON (p < 0.05) 
e  Significantly different from HFCON (p < 0.05) 
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 The HF diet and CLA treatment both decreased the proportion of fatty acids 
derived from de novo lipogenesis, i.e. those <16 carbons in length (p < 0.0001; Tables 4 
and 5 and Figure 3A).  The sum of 16C fatty acids was also reduced in milk fat and milk 
clot fat by both treatments (p < 0.0001).  Conversely, the proportion of long chain fatty 
acids (>16C) was increased by the HF diet and CLA treatment (p < 0.0001).  Changes in 
fatty acid distribution due to diet were typically greater in magnitude than those due to 
CLA treatment.  Interactions between diet and CLA were observed for clots; CLA caused 
greater reductions in <16C and 16C fatty acids when the HF diet was fed than when the 
LF diet was fed (p = 0.02 and p <0.0001, respectively). 
 To take into account the possible dilution of short and medium chain fatty acids in 
milk fat by an increase in long chain fatty acids, fatty acid distribution was also expressed 
as the total content of fatty acids by source in whole milk rather than milk fat (Figure 
3B).  This parameter was obtained by multiplying the concentrations of <16C, 16C, and 
>16C fatty acids in milk fat by the milk fat percent of the dam.  This analysis revealed 
that the HF diet and CLA both decreased the proportion of <16C and 16C fatty acids (p < 
0.0001 for diet and CLA effects on both <16C and 16C fatty acids), whereas only the HF 
diet increased the proportion of >16C fatty acids in milk (p < 0.001 for diet, p = 0.78 for 
CLA).  The HF diet and CLA reduced the content of <16C fatty acids in milk by 30-31% 
alone and 68% in combination.  The proportion of >16C fatty acids in milk was increased 
90-92% by the HF diet.  No interactions between diet and CLA were observed.   
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 FIGURE 3.   Effect of dietary fat level and trans-10, cis-12 conjugated linoleic acid 
(CLA) on concentrations of fatty acids of varying chain length in milk fat (A) and whole 
milk (B) of lactating C57Bl/6J mice.  Treatments were LFCON (4% fat diet, no CLA), 
LFCLA (4% fat diet, 20 mg/d CLA), HFCON (24% fat diet, no CLA), and HFCLA (24% 
fat diet, 20 mg/d CLA).  Diets were fed to dams for 7 d in midlactation; CLA was orally 
administered for the last 5 d of the treatment period.  Fatty acids <16 carbons are derived 
from mammary de novo lipogenesis, and fatty acids >16 carbons are taken up preformed 
from plasma.  Fatty acids 16 carbons in length originate from both sources.  Values are 
LS means + SEM; n = 7 for LFCON, and n = 8 for all other treatments. 
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Comparable analysis of the fatty acid distribution in whole clots revealed that 
both the HF diet and CLA significantly altered the clot content of <16C, 16C, and >16C 
fatty acids (p < 0.001; data not shown).  However, CLA increased the proportion of >16C 
fatty acids by only 11-12%, compared to a 101-102% increase due to the HF diet.  The 
concentration of >16C fatty acids in clots was decreased 37% by the HF diet alone, 46% 
by CLA alone, and 70% by the HF diet and CLA in combination.  An interaction between 
diet and CLA was observed such that CLA caused a lesser reduction in 16C fatty acids in 
combination with the HF diet than alone (p < 0.0001). 
 
Histology 
 Mammary tissue from a subset of dams (n = 4) from each treatment group was 
examined, and no discernable differences in tissue architecture, prevalence of cell 
populations, or cell morphology were observed among treatments (data not shown).   
 
DISCUSSION 
 
 Consistent with previous studies investigating the effects of CLA isomers on 
rodent lactation (3, 35, 36, 41), treatment with trans-10, cis-12 CLA decreased milk fat 
percent in lactating mice (Table 3).  However, the magnitude of this reduction was less 
than expected based on a previous dose-response experiment completed in our lab (3).  In 
the present study, oral administration of 20 mg/d of CLA caused a 12% decrease in milk 
fat percent and the incorporation of CLA into milk fat at a concentration of 0.61 g/100 g 
of fatty acids for mice on the LF diet (Tables 3 and 4).  In contrast, in our earlier study, 
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the same dose previously produced a 20% decrease in milk fat percent and the 
incorporation of CLA into milk fat at 1.35 g/100 g (3).  The response in the present 
experiment was more similar to that when mice were treated with a lower dose of 6.5 
mg/d of CLA, which decreased milk fat by 11% and resulted in 0.47 g/100 g CLA in 
milk fat (3).  The length, timing, and method of CLA treatment were the same in both 
studies.  In the dose-response experiment (3), mice were fed a chow diet containing 5% 
fat, compared to a semi-purified diet containing 4% fat in the current study (Table 1).  
Although the nutrient composition of the diets was similar, the absorption of fatty acids 
may be influenced by whether they are supplied in conjunction with a semi-purified diet 
or a chow diet.  An additional difference is that in the present study, the CLA stock was 
further purified before administration by extraction using hexane:isopropanol.  This 
process may have removed salts or other compounds that aid the absorption of fatty acids 
in the gut.  This could have reduced the absorption of CLA in the intestine such that the 
effective dose was lower in the present experiment.  This is supported by the fact that the 
magnitude of the reduction in milk fat percent due to CLA treatment was consistent with 
the degree of incorporation of CLA into milk fat based results obtained when a lower 
dose of CLA (6.5 mg/d) was administered (3).   
A reduction in short and medium chain fatty acids was primarily responsible for 
the decrease in milk fat due to treatment with CLA (Table 4 and Figure 3).  These fatty 
acids are derived from de novo lipogenesis in the mammary gland, which involves the 
enzymes acetyl CoA carboxylase (ACC) and fatty acid synthase (FASN).  ACC catalyzes 
the first and rate-limiting step in fatty acid synthesis, the conversion of acetyl CoA into 
malonyl CoA, and FASN is a multi-enzyme complex that catalyzes a sequence of seven 
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reactions in which two-carbon units from malonyl CoA are added to the growing fatty 
acyl chain (38).  The mammary activity and expression of ACC and FASN are reduced 
by CLA treatment in rodents (3, 35, 36, 44) and cows (2, 20).  As noted previously, the 
expression of genes encoding these key lipogenic enzymes and others is regulated by the 
transcription factor SREBP1c, and CLA is thought to inhibit the proteolytic cleavage of 
SREBP1c that is required for it to function as a transcriptional activator (22).  Thus, CLA 
treatment appears to decrease de novo lipogenesis by inhibiting the activation of 
SREBP1c, which results in a reduction in the transcription of lipogenic genes such as 
ACC and FASN. 
A decrease in the synthesis of short and medium chain fatty acids would result in 
an increase in the proportion of long chain fatty acids that are incorporated into milk fat.  
This was indeed observed in response to CLA treatment (Figure 3A), but after accounting 
for the decrease in milk fat percent, the total content of >16C fatty acids in whole milk 
was not affected by CLA (Figure 3B).  This is in contrast to observations in the cow that 
the reduction in milk fat yield due to CLA treatment involves fatty acids of all chain 
lengths (8).  Conclusions based on milk fat yield are not strictly comparable to those 
based only on milk composition, but in the cow, treatment with CLA does not affect milk 
yield (8).  Thus, the contribution of different fatty acids to milk fat yield should reflect 
their concentrations in whole milk.  To the best of our knowledge, the effect of CLA on 
milk production in mice has not been determined due to the greater difficulty of 
measuring milk yield in rodents.  If milk yield is indeed unaffected by CLA as it is in the 
cow, the lack of a reduction in >16C fatty acids in milk may represent a lesser effect of 
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CLA on the incorporation of preformed long chain fatty acids into milk fat in the mouse 
than in the cow.   
An important enzyme in this process is lipoprotein lipase (LPL), which cleaves 
fatty acids from circulating lipoproteins to allow their uptake into cells and subsequent 
re-esterification for secretion in milk fat.  Transcription of the gene encoding LPL is 
stimulated by SREBP1c, and LPL expression is downregulated in cows treated with CLA 
(2, 22).  Measurements of gene expression in the rodent mammary gland during treatment 
with CLA found no difference (3) or a decrease (35) in the abundance of LPL mRNA.  
Replication of these measurements as well as determination of LPL activity and the 
expression of fatty acid binding proteins (FABP) would help elucidate whether the uptake 
of preformed fatty acids by the mammary gland is less responsive to CLA in rodents than 
in cows. 
The decrease in milk fat percent due to CLA treatment was accompanied by 
reductions in the growth rate of the nursing litter and the energy intake of the dam (Table 
3 and Figure 2).  These responses are probably a direct result of the decreased energy 
content of the milk.  Fat is the major energy source in milk, and its synthesis presents a 
significant energetic cost to the lactating dam (1).  Assuming no change in milk yield, 
any treatment that decreases milk fat percent would thus be expected to decrease pup 
growth and the energy requirement of the dam.  This would in turn decrease energy 
intake, as this parameter is highly correlated with energy demand in lactating rodents.  
For instance, decreasing the energetic cost of lactation by artificially reducing litter size 
leads to a decrease in energy intake (60), and increasing maintenance energy 
requirements by keeping mice in a cold environment results in greater energy intake (61).  
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Similarly, pup growth is positively correlated with milk fat percent across mouse strains 
(40) and when milk fat percent is altered by varying the fat content of the diet (39). 
As increased intake of dietary fat often results in greater milk fat percent, we 
sought to determine whether feeding a high fat diet would overcome the reduction in milk 
fat induced by CLA treatment.  The fat content of the experimental diet was increased by 
substituting high oleic sunflower oil for cornstarch to keep the density of other nutrients 
such as protein constant when expressed on an energy basis (Table 1).  Soybean oil was 
included in both experimental diets to provide essential fatty acids.  High oleic acid 
sunflower oil was chosen as the primary fat source to provide fatty acids that could be 
readily incorporated into milk fat but that lacked significant bioactive properties.  Oils 
rich in medium chain fatty acids were avoided because these fatty acids are extensively 
oxidized in the liver, reducing their availability to the mammary gland (6, 54).  An oil 
low in polyunsaturated fatty acids was desired because some of these fatty acids are 
reported to regulate gene transcription (55).  The sunflower oil selected contained 
approximately 85% oleic acid; oleic acid thus comprised 46% and 78% of the fatty acids 
by weight in the LF and HF diets, respectively (Table 2).  With the exception of oleic 
acid and 14:1c9, all fatty acids measured were found in greater proportion in the LF diet 
than in the HF diet. 
The HF diet resulted in an increase in milk fat percent (Table 3), and the 
composition of milk fat reflected that of dietary fat (Tables 2 and 4).  The observed 
increase in oleic acid in milk fat was particularly striking; it rose from 29 to 56 g/100 g of 
fatty acids in the control mice when the HF diet was fed (Table 4).  This increase was 
predominantly due to incorporation of dietary oleic acid into milk fat, as long chain fatty 
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acids are not synthesized in the mammary gland.  In addition to an increase in the 
proportion of fatty acids taken up preformed from plasma, the fatty acid profile of milk 
fat also reflected a reduction in the proportion of fatty acids derived from de novo 
lipogenesis (Table 4, Figure 3A).  Accounting for the increase in milk fat percent 
revealed that this was not merely due to dilution of short and medium chain fatty acids by 
an increase in long chain fatty acids (Figure 3B).  Thus an inhibition of de novo 
lipogenesis was likely, as has been demonstrated by decreased rates of mammary 
lipogenesis in rodents fed high fat diets (4-6).  Inhibition of ACC by non-esterified fatty 
acids has been proposed as a mechanism for the reduction in lipogenesis due to increased 
dietary fat (38). 
 Although the HF diet increased milk fat percent, litter growth rate was only 
numerically increased (Table 3).  Several studies have reported the similar results (6, 47, 
48, 51, 52), whereas others have observed significant increases in pup growth (5, 39, 45).  
As discussed previously, differences in methodology may have contributed to this 
inconsistency.  An increase in energy intake was seen for dams on the HF diet (Table 3).  
This was may have been related the greater palatability of the diet, as mice were observed 
to overeat when first offered the HF diet (Figure 2B).  Energy intake on the second day 
was closer to that of mice on the LF diet, but it remained elevated for the duration of the 
treatment period.  Del Prado et al. (39) compared milk fat synthesis and litter growth for 
lactating rats fed low or high fat diets ad libitum or pair fed the high fat diet on an equal 
energy basis to rats consuming the low fat diet.  They found that elevated fat content in 
the diet increased milk fat percent and litter growth irrespective of energy consumption.  
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Therefore, the observed increase in milk fat content for dams on the HF diet in the 
present experiment was likely not solely a consequence of increased energy intake.   
Although increased dietary fat intake caused an increase in milk fat percent, it was 
unable to overcome the CLA-induced inhibition of milk fat synthesis (Table 3).  Milk fat 
content was decreased equally by CLA for mice fed either diet.  Whereas the HF diet 
increased the incorporation of dietary long chain fatty acids into milk fat, it inhibited the 
synthesis of short and medium chain fatty acids to an equal or greater extent than did 
CLA treatment (Figure 3B).  Transfer of dietary fatty acids to milk fat was, therefore, not 
enough to compensate for the reduction in lipogenesis, so no interaction was found 
between diet and CLA (Table 3).  Interactions were observed for other parameters, such 
as energy intake (Table 3).  The greater palatability of the HF diet presumably caused the 
CLA-treated dams to consume energy in excess of their requirements.  Consistent with 
this hypothesis, the body weight of HFCLA dams changed by +0.07 g/d during the 
treatment period compared to a change of -0.15 g/d for the LFCLA dams (Table 3).  
However, variation in recorded weights was high due to movements of the dams during 
weighing, so neither treatment significantly differed from its respective control.  
Interactions between feed and CLA were also noted for the concentrations of multiple 
fatty acids in milk fat and clot fat, but in only three cases (10:0, 16:1c9, and 20:0) was the 
same effect observed for the same fatty acid in both milk and clot fat (Tables 4 and 5).  A 
reason for these interactions is not apparent.   
In general, effects of diet and CLA on the fatty acid profile of milk clots reflected 
changes in milk fatty acid composition, but differences in the concentrations of individual 
fatty acids were observed (Tables 4 and 5).  These are thought be related to circadian 
35 
 
patterns of feed consumption and lipogenesis as well as differences in the timing of milk 
and clot collection with respect to the photoperiod and the final CLA dose.  Feed intake 
by lactating rodents is greatest at night, and this is associated with a peak in mammary 
lipogenesis due to the greater availability of substrates for fatty acid synthesis (39).  
Dams in the present experiment were milked in the afternoon, which coincides with a 
period of lower feed intake and lipogenesis.  In contrast, milk clots from the stomachs of 
pups provide a composite of milk samples over time; labeled milk can be recovered from 
clots up to 20 h after its ingestion by rat pups (62).  Therefore, the fatty acid profile of 
clots exhibits less diurnal variation.  Indeed, the proportions of >16C and 16C fatty acids 
in clot fat were greater than those in milk fat, since clots presumably reflected the fatty 
acid composition of milk synthesized during the period of greater lipogenesis during the 
preceding night rather than just during the day (Tables 4 and 5).  The concentration of 
CLA in clot fat was less than that measured in milk fat (Tables 4 and 5).  This was also 
related to the timing of milking and clot collection.  Clots were recovered 2-3 h after the 
final dose of CLA was administered, leaving little time for ingested CLA to be absorbed 
by the dam, incorporated into milk fat, and consumed by the pups.  Thus the milk most 
recently ingested was produced toward the end of the interval between CLA doses and 
likely contained less CLA.  On the other hand, dams were milked 5-6 h after the last CLA 
dose, so the composition of milk fat reflected greater availability of absorbed CLA for 
incorporation into milk fat.    
Biological effects of CLA isomers have been observed in many tissues and cell 
types, and a number of mechanisms have been investigated.  The reductions in body fat 
accretion and carcinogenesis attributed to isomers of CLA have been linked to increased 
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apoptosis of adipocytes (63) and neoplastic mammary epithelial cells (64).  High 
concentrations of trans-10, cis-12 CLA have been shown to induce apoptosis in cultured 
bovine mammary epithelial cells, and this has been proposed as a mechanism for the 
effects of CLA on lactation (65).  Increased cytokine expression and macrophage 
infiltration have also been observed in adipose tissue of rodents treated with CLA (66).  
In the present study, examination of mammary tissue from mice treated with CLA 
yielded no signs of inflammation or increased apoptosis.  No gross differences were 
discernable among treatments, thus, these mechanisms were unlikely to have contributed 
to alterations in milk composition.  
In conclusion, treatment of lactating mice with trans-10, cis-12 CLA decreased 
milk fat percent and growth of the nursing litter.  This was not overcome by increased 
intake of dietary fat, although milk fat percent was greater for mice fed a high fat diet 
than those fed a low fat diet.  Both CLA treatment and consumption of a high fat diet 
resulted in changes in the fatty acid profile of milk fat that suggested depressed de novo 
lipogenesis in the mammary gland.  The high fat diet, but not CLA, increased the 
incorporation of preformed fatty acids derived from plasma into milk fat.  These long 
chain fatty acids originated primarily from the diet, and substantial transfer of dietary 
oleic acid to milk fat was observed for mice fed a high fat diet rich in oleic acid.  The 
composition of milk clots collected from the stomachs of nursing pups reflected that of 
milk, but some differences were noted.  Histological observations of mammary tissue did 
not support CLA-induced inflammation or apoptosis of mammary epithelial cells as 
potential mechanisms for the observed decreases in lipogenesis and milk fat percent in 
response to CLA treatment.  Alternatively, a mechanism was discussed involving reduced 
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activation of the transcription factor SREBP1c, resulting in decreased expression of genes 
encoding key lipogenic enzymes in the mammary gland. 
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